title: [Malignant neuroleptic syndrome and Clostridium difficile: causal association or mere coincidence?].
authors.forename: R
authors.initials: R
authors.lastname: Salas de Zayas
authors.forename: C
authors.initials: C
authors.lastname: Cerdeño Gómez
authors.forename: C
authors.initials: C
authors.lastname: Dolera Moreno
authors.forename: E
authors.initials: E
authors.lastname: Mármol
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000302:isolation & purification*; D003015:Clostridium Infections / Q000150:complications*; D003131:Combined Modality Therapy; D003620:Dantrolene / Q000627:therapeutic use; D003681:Dehydration / Q000209:etiology / Q000378:metabolism; D003937:Diagnosis, Differential; D005260:Female; D005440:Fluid Therapy; D006220:Haloperidol / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy; D012307:Risk Factors; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D001971:Bromocriptine; D003620:Dantrolene; D006220:Haloperidol